Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

NCT01341301 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Hematologic Malignancy

Interventions

RADIATION: Total Body Irradiation
BIOLOGICAL: Donor Lymphocyte Infusion (DLI)
DRUG: Cyclophosphamide
DRUG: Tacrolimus
DRUG: Mycophenolate mofetil
PROCEDURE: Allogeneic hematopoietic stem cell transplantation
OTHER: Laboratory biomarker analysis

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University